VERU INC
VERUNASDAQTrading Snapshot
- Day Range
- $714.08 – $722.86
- 52-Week Range
- $2.05 – $7.33
- Volume
- $2.42B
- Avg Volume
- $2.80B
- Shares Outstanding
- 16.1M
- Next Earnings
- Nov 22, 2026
Fundamentals Snapshot
- Annual Revenue
- $17M
- Last Q Revenue
- $4M
- P/E Ratio
- —
- P/S Ratio
- 2.6x
- EPS (TTM)
- $-0.59
- Dividend Yield
- —
- Dilution (1yr)
- +38.8%
Why Investors Own VERU
- ✓High-growth profile — revenue up +14.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 58% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
VERU INC
VERU
StockOtter · stockotter.spaceAbout VERU INC
Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of investigational therapies, notably within oncology: Enobosarm, an orally administered selective androgen receptor agonist, is progressing through Phase III clinical trials for treating metastatic breast cancer that is AR+, ER+, and HER2-negative. Sabizabulin is undergoing Phase IIb studies for the same type of metastatic breast cancer. Furthermore, a combination therapy of Enobosarm with abemaciclib is in Phase III for AR+ ER+ HER2- metastatic breast cancer. For metastatic triple-negative breast cancer, Veru is exploring a combination of Sabizabulin (an oral targeted cytoskeleton disruptor) and Enobosarm (a selective androgen receptor agonist) in Phase II trials. The company's portfolio also extends to prostate cancer: Sabizabulin is in Phase II trials for metastatic castration and androgen receptor targeting agent-resistant prostate cancer. VERU-100, a GnRH antagonist peptide delivered via injection, is also in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru is investigating other conditions: Zuclomiphene Citrate is in Phase II for managing hot flashes. Sabizabulin has reached Phase III for treating SARS-CoV-2 in high-risk patients susceptible to acute respiratory distress syndrome. Additionally, the firm is developing a novel pharmaceutical formulation aimed at alleviating lower urinary tract symptoms associated with an enlarged prostate in men. Originally established as The Female Health Company in 1971, the corporation adopted the name Veru Inc. in July 2017. Its corporate headquarters are situated in Miami, Florida.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
VERU INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift VERU price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
VERU INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.